As the global healthcare system re-equilibrates post-pandemic, the biopharmaceutical industry has resumed pre-COVID-19 levels of investment, pipeline activity, and launch of novel medicines following record breaking levels of each in 2020 and 2021. Process and technology innovations that were accelerated by extreme circumstances during the pandemic are being integrated across the global pipeline and implemented as operational and organizational changes that are enabling ongoing productivity gains.
This report assesses the trends in new drug approvals and launches, overall pipeline activity in terms of actively researched medicines, and the number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types, and the results of research are compared to the input effort in a Clinical Development Productivity Index. This set of analyses reveals important shifts in therapeutic and geographic investments and ongoing prioritization of novel mechanisms of action, innovative development methods and accelerated regulatory pathways to optimize new therapy development and delivery to patients. This work also examines changes in the Productivity Index driven by shifting pipeline complexity and probability of success.